These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30514711)

  • 1. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
    Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
    Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion.
    Hasegawa T; Murakawa S; Maruko I; Kogure-Katakura A; Iida T
    Br J Ophthalmol; 2019 Jan; 103(1):72-77. PubMed ID: 29545416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT.
    Terashima H; Hasebe H; Okamoto F; Matsuoka N; Sato Y; Fukuchi T
    Retina; 2019 Jul; 39(7):1377-1384. PubMed ID: 29689025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2019 Aug; 139(1):67-74. PubMed ID: 30980231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal imaging to distinguish microvascular and morphological changes in retinal vein occlusion after intravitreal ranibizumab with or without triamcinolone acetonide injection.
    Wang N; Zou J; Li S; Deng X; Zeng J; Ding C
    BMC Ophthalmol; 2024 Aug; 24(1):354. PubMed ID: 39164640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
    Nishimura T; Machida S; Tada A; Oshida E; Muto T
    Doc Ophthalmol; 2020 Oct; 141(2):127-136. PubMed ID: 32100140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
    Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
    PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
    Son BK; Kwak HW; Kim ES; Yu SY
    Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between macular vessel density and number of intravitreal anti-VEGF agents for macular edema associated with branch retinal vein occlusion.
    Tomita R; Iwase T; Goto K; Yamamoto K; Ra E; Terasaki H
    Sci Rep; 2019 Nov; 9(1):16388. PubMed ID: 31705014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
    Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
    Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
    [No Abstract]   [Full Text] [Related]  

  • 13. SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION.
    Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
    Retina; 2016 Sep; 36(9):1726-32. PubMed ID: 26866527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab.
    Asano T; Kunikata H; Yasuda M; Nishiguchi KM; Abe T; Nakazawa T
    Int Ophthalmol; 2021 Jan; 41(1):151-162. PubMed ID: 32894391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years.
    Rezar S; Eibenberger K; Bühl W; Georgopoulos M; Schmidt-Erfurth U; Sacu S;
    Acta Ophthalmol; 2015 Dec; 93(8):719-25. PubMed ID: 26109209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy.
    Suzuki M; Nagai N; Minami S; Kurihara T; Kamoshita M; Sonobe H; Watanabe K; Shinoda H; Tsubota K; Ozawa Y
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):49-56. PubMed ID: 31732812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
    Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
    Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections.
    Miwa Y; Muraoka Y; Osaka R; Ooto S; Murakami T; Suzuma K; Takahashi A; Iida Y; Yoshimura N; Tsujikawa A
    Retina; 2017 Apr; 37(4):702-709. PubMed ID: 27471827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.